Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and Beyond.

Front Med (Lausanne) · 2022 · PMC9086587 · PMID 35559349

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend in the use of QoNM by pharmaceutical companies had previously been identified ( 33 ), suggesting that companies are more likely to include biomarker-related questions in SA procedures.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.